Bristol-Myers Squibb Company - Product Pipeline Review - 2015

  • ID: 3338412
  • Company Profile
  • 240 pages
  • Global Markets Direct
  • Bristol-Myers Squibb
1 of 4
Bristol-Myers Squibb Company - Product Pipeline Review - 2015

Summary

This, ‘Bristol-Myers Squibb Company - Product Pipeline Review - 2015’, provides an overview of the Bristol-Myers Squibb Company’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bristol-Myers Squibb Company’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bristol-Myers Squibb Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bristol-Myers Squibb Company’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Bristol-Myers Squibb Company’s pipeline products

Reasons to buy

- Evaluate Bristol-Myers Squibb Company’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bristol-Myers Squibb Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bristol-Myers Squibb Company’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bristol-Myers Squibb Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bristol-Myers Squibb Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bristol-Myers Squibb Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Bristol-Myers Squibb Company Snapshot
Bristol-Myers Squibb Company Overview
Key Information
Key Facts
Bristol-Myers Squibb Company - Research and Development Overview
Key Therapeutic Areas
Bristol-Myers Squibb Company - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Bristol-Myers Squibb Company - Pipeline Products Glance
Bristol-Myers Squibb Company - Late Stage Pipeline Products
Bristol-Myers Squibb Company - Clinical Stage Pipeline Products
Bristol-Myers Squibb Company - Early Stage Pipeline Products
Bristol-Myers Squibb Company - Drug Profiles
daclatasvir dihydrochloride
ipilimumab
nivolumab
daclatasvir dihydrochloride + asunaprevir
(daclatasvir dihydrochloride + asunaprevir + beclabuvir)
abatacept
apixaban
beclabuvir
brivanib alaninate
fostemsavir tromethamine
BMS-754807
BMS-813160
BMS-833923
BMS-919373
BMS-955176
BMS-986020
BMS-986036
dasatinib
denenicokin
eldelumab
lirilumab
lulizumab pegol
urelumab
BMS-911543
BMS-986004
BMS-986012
BMS-986148
BMS-986158
ulocuplumab
Antibody to Target CD40 Ligand for Immunology
BMS-241027
BMS-262084
BMS-777607
BMS-906024
BMS-962476
BMS-963272
BMS-981164
BMS-986016
BMS-986089
BMS-986090
BMS-986104
BMS-986115
BMS-986120
BMS-986141
BMS-986142
BMS-986147
BMS-986168
FLX-925
FS-102
Iso-fludelone
ixabepilone
MDX-1303
Small Molecule for Cancer
Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases
Small Molecule to Antagonize PAR4 for Thromboembolic Disorders
Small Molecule to Inhibit IRAK4 for Immunology
Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity
BMS-817378
ALB-109780
AMR-2
ARX-720
BMS-457
BMS-585248
BMS-593214
BMS-795311
BMS-816106
BMS-869780
BMS-871
BMS-884775
Drug for Metabolic Disorders
F-001287
Small Molecule to Agonize Kv7.2 for Neuropathic Pain and Diabetic Neuropathy
Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity
Small Molecule to Antagonize NK1R and Block SERT for Depression
Small Molecule to Inhibit Factor XIa for Thrombosis
Small Molecule to Inhibit IAP for Melanoma
Small Molecules to Antagonize NR2B for Major Depression
Small Molecules to Inhibit ROR-Gamma for Inflammation
Monoclonal Antibody Conjugates for Oncology
Proteins for Immunology and Cancer
Small Molecules for Undisclosed Indication
Small Molecules to Inhibit IDO and TDO for Oncology
Small Molecules to Inhibit IDO for Oncology
Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases
Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders
Small Molecules to Inhibit TDO for Oncology
Bristol-Myers Squibb Company - Pipeline Analysis
Bristol-Myers Squibb Company - Pipeline Products by Target
Bristol-Myers Squibb Company - Pipeline Products by Route of Administration
Bristol-Myers Squibb Company - Pipeline Products by Molecule Type
Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action
Bristol-Myers Squibb Company - Recent Pipeline Updates
Bristol-Myers Squibb Company - Dormant Projects
Bristol-Myers Squibb Company - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Bristol-Myers Squibb Company - Company Statement
Bristol-Myers Squibb Company - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Bristol-Myers Squibb Company - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Bristol-Myers Squibb Company, Key Information
Bristol-Myers Squibb Company, Key Facts
Bristol-Myers Squibb Company - Pipeline by Indication, 2015
Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2015
Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2015
Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2015
Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2015
Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2015
Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2015
Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2015
Bristol-Myers Squibb Company - Pre-Registration, 2015
Bristol-Myers Squibb Company - Filing rejected/Withdrawn, 2015
Bristol-Myers Squibb Company - Phase III, 2015
Bristol-Myers Squibb Company - Phase II, 2015
Bristol-Myers Squibb Company - Phase I, 2015
Bristol-Myers Squibb Company - IND/CTA Filed, 2015
Bristol-Myers Squibb Company - Preclinical, 2015
Bristol-Myers Squibb Company - Discovery, 2015
Bristol-Myers Squibb Company - Pipeline by Target, 2015
Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2015
Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2015
Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2015
Bristol-Myers Squibb Company - Recent Pipeline Updates, 2015
Bristol-Myers Squibb Company - Dormant Developmental Projects,2015
Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2015
Bristol-Myers Squibb Company, Other Locations
Bristol-Myers Squibb Company, Subsidiaries
Bristol-Myers Squibb Company, Key Manufacturing Facilities

List of Figures
Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2015
Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2015
Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2015
Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2015
Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2015
Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2015
Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2015
Bristol-Myers Squibb Company - Pipeline by Top 10 Route of Administration, 2015
Bristol-Myers Squibb Company - Pipeline by Top 10 Molecule Type, 2015
Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll